Rege Nephro Co., Ltd. (Headquarters: Sakyo-ku, Kyoto, Japan; Representative Director: Akifumi Morinaka; hereafter “Rege Nephro”) announces that Director Akifumi Morinaka has been appointed as Representative Director as of July 3, 2023.
<Profile of Akifumi Morinaka>
After graduating from the Faculty of Science at the University of Tokyo, he completed the Graduate School of Frontier Sciences at the same university and received PhD in life sciences. He also completed an MBA from Waseda University Graduate School of Business Administration.
At Astellas Pharma Inc., he was engaged in drug discovery research, personalized medicine, translational research, and new business creation in medical devices and digital health. He then moved to CVC. to work with medical device VC in Silicon Valley.
He then joined JAFCO, where he invested in biotech startups, mainly in life science. He has also served as a board member of companies he invested in and supported their growth, supported the creation of university-launched startups as a business promoter for JST START, and supported the development of drugs, medical devices, and regenerative medicine as a supporter of MEDISO.
<Comment from Akifumi Morinaka, Representative Director of Rege Nephro>
I am truly honored to serve as Representative Director of Rege Nephro. I will mobilize all of my experience from basic research at universities, drug discovery research and new business creation at pharmaceutical a company, and venture investment and incubation at a venture capital firm to grow the company.
The excellent seeds developed from many years of research by our founding scientist, Professor Osafune, have been nurtured from the ground up by our former president, Mr. Ishikiriyama. I will do my utmost to carry on the baton and contribute to patients suffering from intractable renal diseases as soon as possible.
<Rege Nephro Overview>
Rege Nephro Co., Ltd.
Representative Director: Akifumi Morinaka
Address: Med-Pharm Collaboration bldg, Kyoto University, 46-29 Yoshidashimoadachi-cho, Sakyo-ku, Kyoto, Japan
Business: Research, development, production and sales of renal diseases treatment technology
Establishment: September 2019
<inquiries regarding this matter>
Masanori Uchida (Administrative Director)